Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer | Zendy

Barbara Melosky | Zendy; Normand Blais | Zendy; Parneet Cheema | Zendy; Christian Couture | Zendy; Rosalyn A. Juergens | Zendy; Suzanne KamelReid | Zendy; MingSound Tsao | Zendy; Paul WheatleyPrice | Zendy; Zhaolin Xu | Zendy; Dia. Ionescu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer

Author(s) -

Barbara Melosky,

Normand Blais,

Parneet Cheema,

Christian Couture,

Rosalyn A. Juergens,

Suzanne KamelReid,

MingSound Tsao,

Paul WheatleyPrice,

Zhaolin Xu,

Dia. Ionescu

Publication year - 2018

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.25.3867

Subject(s) - medicine , kras , lung cancer , oncology , neuroblastoma ras viral oncogene homolog , ros1 , biomarker , context (archaeology) , anaplastic lymphoma kinase , cancer , epidermal growth factor receptor , adenocarcinoma , paleontology , biochemistry , chemistry , colorectal cancer , malignant pleural effusion , biology

The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (nsclc) has significantly improved patient survival rates and quality of life. Biomarker testing for patients newly diagnosed with nsclc, as well as for patients progressing after treatment with epidermal growth factor receptor ( EGFR ) inhibitors, is the standard of care in Canada and many parts of the world.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research